Last $20.61 USD
Change Today +0.37 / 1.83%
Volume 74.4K
INGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 4:00 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

inogen inc (INGN) Snapshot

Open
$20.29
Previous Close
$20.24
Day High
$20.73
Day Low
$20.13
52 Week High
09/9/14 - $24.50
52 Week Low
05/6/14 - $13.12
Market Cap
375.9M
Average Volume 10 Days
81.1K
EPS TTM
--
Shares Outstanding
18.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INOGEN INC (INGN)

Related News

No related news articles were found.

inogen inc (INGN) Related Businessweek News

No Related Businessweek News Found

inogen inc (INGN) Details

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic obstructive pulmonary disease and other chronic respiratory conditions. It offers Inogen One systems, which are portable devices that concentrate the air around them to offer a single source of supplemental oxygen; and related accessories to patients, insurance carriers, home healthcare providers, and distributors. The company sells its products in the United States and internationally. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

354 Employees
Last Reported Date: 04/1/14
Founded in 2001

inogen inc (INGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $346.9K
Co-Founder, Chief Financial Officer, Principa...
Total Annual Compensation: $203.5K
Executive Vice President of Sales & Marketing
Total Annual Compensation: $215.9K
Compensation as of Fiscal Year 2013.

inogen inc (INGN) Key Developments

Inogen, Inc. Announces Reimbursement for Inogen One G3 in France

Inogen, Inc. announced that the Inogen One G3 portable oxygen concentrator has received coverage for reimbursement within France. The Department of Social Affairs and Health in France has added the Inogen One G3 to its list of reimbursable oxygen therapy products and services. Inogen One G3 is classified under long-term oxygen therapy for ambulation and requires a physician prescription. Inogen One G2 portable oxygen concentrator received similar coverage in France in mid-2013.

Inogen, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Inogen, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenue rose 50.8% to $30.4 million, from $20.2 million in same period in 2013. Sales revenue was $20.5 million, up from $12.8 million, a 60.5% increase from the 2013 period, due to the growth in its direct-to-consumer sales and its business-to-business sales worldwide. Adjusted EBITDA was $7.4 million, up 68.4% from $4.41 million for the same period in the prior year and representing a 24.4% return on revenue, demonstrating substantial cost leverage across sales and marketing, research and development, and general and administrative expenses. Net income was $2.3 million, or $0.11 per diluted common share on a pro-forma non-GAAP basis, compared with $2.0 million, or $0.12 per diluted common share on a pro-forma non-GAAP basis, in the same period in 2013. Income from operations was $3.96 million compared to $2.39 million a year ago. Income before provision for income taxes was $3.78 million compared to $3.04 million a year ago. Net income was $2.3 million, or $0.11 per diluted common share on GAAP basis compared with $1.96 million, or $0.00 per diluted common share on GAAP basis, in the same period in 2013. For the six months, total revenue rose 50.5% to $54.0 million, from $35.9 million in the first-half of 2013. Sales revenue was $35.3 million, up from $21.6 million, a 63.2% increase from the first six months of 2013. Net income was $3.2 million compared to $2.69 million a year ago. Diluted earnings per share attributable to common stockholders was $0.11 on GAAP basis, or $0.16 per diluted common share on a pro-forma non-GAAP basis compared to $2.98 on GAAP basis and $0.17 on Non-GAAP basis a year ago. Income from operations was $5.51 million compared to $3.03 million a year ago. Income before provision for income taxes was $5.24 million compared to $2.80 million a year ago. Adjusted EBITDA was $11.78 million compared to $6.94 million a year ago. The company provided earnings guidance for the year 2014. The company expects similar sales seasonality as it has seen historically, where patient demand is the high in the second quarter. The company projects total revenue for 2014 to be in the range of $102.0 to $106.0 million, an increase of 35.2% to 40.5% over 2013 revenue. This compares to the previous revenue expectation of $92.0 to $96.0 million which was provided on May 13, 2014. Adjusted EBITDA is projected to be in the range of $19.0 to $20.5 million which is updated from the previous range of $18.0 to $19.5 million. Net income is projected to be in the range of $4.5 to $5.5 million, which is updated from the previous guidance of $4.0 to $5.0 million.

Inogen, Inc. Announces Board Changes

Inogen, Inc. announced that Heather D. Rider has been elected to its Board of Directors, effective immediately. In addition, Ms. Rider was appointed to the Board's Compensation, Nominating and Governance Committee replacing Benjamin Anderson-Ray who has joined the Board's Audit Committee, effective immediately. She will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held in 2015. Ms. Rider fills the vacancy created by the resignation of Charles Larsen. Mr. Larsen has served as a member of Inogen's Board since 2006.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INGN:US $20.61 USD +0.37

INGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Invacare Corp $11.81 USD -0.48
View Industry Companies
 

Industry Analysis

INGN

Industry Average

Valuation INGN Industry Range
Price/Earnings 71.3x
Price/Sales 3.9x
Price/Book 3.3x
Price/Cash Flow 14.2x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOGEN INC, please visit www.inogen.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.